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Performance estimate of drug, e.g. probability of cure 
Preference estimate, e.g. the added utility of 1% more probability of cure 
Part-worth utility that is yielded by the performance in (1) for a patient with 
the preference in (2) 
Probability distribution of the performance of the drug 
A performance sample from the performance distribution 
Probability distribution of the preferences of the patient (population) 
A sampled preference representing an individual patient 
Part-worth utility that corresponds to the samples in steps (5) and (7) 
Repeating this process a large number of times in a Monte Carlo simulation 
yields a distribution of the part-worth utility of a drug 
Steps (1) through (9) are repeated per treatment for each attribute and the 
results are summed to obtain the probability distribution of each treatment’s 
utility. 
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Virological failure  
(events / nonevents) 
Allergic reaction (events / 
nonevents) 
Bone damage (events / 
nonevents) 
Kidney damage (events / 
nonevents) 
Abacavir/Lamivudine 167 / 574 14 / 329 29 / 561 33 / 689 
Tenofovir/Emtricitabine 140 / 604 8 / 389 18 / 574 51 / 676 
Dolutegravir 85 / 982 1 / 413 0/414 1 / 1066 
Efavirenz 339 / 1884 80 / 1261 49 / 1225 11 / 2074 
Atazanavir/Ritonavi 70 / 826 27 / 437 21 / 443 6 / 458 
Elvitegravir/Cobicistat 43 / 305 0/348 6 / 342 3 / 345 
    Utility (95%CI) 
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Abacavir/Lamivudine -5.3 (-6.3 to -4.4) 
Tenofovir/Emtricitabine -5.3 (-6.2 to -4.35) 
Dolutegravir -2.0 (-2.7 to -1.3) 
Efavirenz -3.8 (-4.5 to -3.0) 
Atazanavir/Ritonavir -3.8 (-4.7 to -2.9) 
Elvitegravir/Cobicistat -2.8 (-3.7 to -2.0) 
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Abacavir/Lamivudine -5.3 (-6.0 to -4.8) 
Tenofovir/Emtricitabine -5.2 (-5.9 to -4.7) 
Dolutegravir -2.0 (-2.1 to -1.9) 
Efavirenz -3.7 (-4.1 to -3.5) 
Atazanavir/Ritonavir -3.8 (-4.4 to -3.3) 
Elvitegravir/Cobicistat -2.8 (-3.4 to -2.4) 
Objectives 
Conclusion 
Quantitative patient preferences are increasingly considered for healthcare policy decisions. The objective of this study is to develop a methodology to combine patient preferences with clinical evidence 
in a multi-criteria framework that takes into account uncertainty in both preferences and clinical evidence. The methodology is illustrated with a case on antiretroviral treatments. 
A probabilistic multi-criteria methodology was developed that explicitly combines patient preferences and clinical evidence. The impact of uncertainty in one or both of these on the treatments’patient-
weighted utilities can be assessed. Although limited by the small number of attributes and preference sample, the illustrative case suggests the choice of HAART is highly sensitive to patient preferences. 
  
𝛽  𝑆𝐸(𝛽 ) 𝜎𝑞 𝑆𝐸(𝜎𝑞) 
Virological failure -0.04 0.01 0.05 0.02 
Allergic reaction -0.06 0.01 0.06 0.02 
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 Treatable -0.01 0.02 0.06 0.06 
Unknown -0.15 0.03 0.06 0.04 
Not treatable -0.21 0.04 0.22 0.06 
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 Treatable -0.05 0.02 0.12 0.02 
Unknown -0.06 0.03 0.03 0.06 
Not treatable -0.17 0.04 0.21 0.05 
